Chimerix Mourns Passing of Director Rodman L. Drake

DURHAM, N.C., June 26, 2014 (GLOBE NEWSWIRE) -- It is with great sadness that Chimerix, Inc. (Nasdaq:CMRX) marks the death of Director Rodman L. Drake.

"We are deeply saddened to learn of Rod's passing. He will be greatly missed," said Ernest Mario, PhD, Chairman of the Board of Directors of Chimerix. "During his tenure with Chimerix, Rod made lasting impressions on everyone that knew him. In addition to being a trusted colleague and adviser, he was a wonderful person and friend. I along with all the members of our Chimerix team offer our deepest sympathies to the Drake family at this time of enormous loss."

Mr. Drake joined the Board of Directors in 2013 and served as Chairman of the Compensation Committee. Among Mr. Drake's many accomplishments, he served as CEO and Managing Director of Cresap McCormick and Paget, a leading international management consulting firm, Co-Chairman of KMR Power Company and President of the Mandrake Group, a consulting firm specializing in strategy and organizational design. Most recently, Mr. Drake served as the Managing Director of Baringo Capital, LLC, a private equity group he co-founded. Mr. Drake earned his MBA from Harvard Business School and his bachelor's degree from Yale University.

About Chimerix

Chimerix is a biopharmaceutical company dedicated to developing and commercializing novel, oral antivirals in areas of high unmet medical need. Chimerix's proprietary technology has given rise to brincidofovir (CMX001), a clinical-stage nucleotide analog lipid-conjugate which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens. Chimerix is currently enrolling SUPPRESS, a Phase 3 study of brincidofovir for the prevention of cytomegalovirus infection in HCT recipients; in addition, Chimerix is enrolling the pilot portion of a Phase 3 study of brincidofovir for treatment of disseminated adenovirus infection. Chimerix is working with the Biomedical Advanced Research and Development Authority to develop brincidofovir as a medical countermeasure against smallpox. For further information, please visit Chimerix's website, www.chimerix.com.

CONTACT: CHIMERIX CONTACT: Joseph T. Schepers Executive Director, Investor Relations and Corporate Communications ir@chimerix.com 919-287-4125Source:Chimerix, Inc.